Is erdafitinib a treatment for urothelial cancer?

Yes, Erdafitinib (Erdafitinib) is a drug used to treat urothelial cancer. Urothelial carcinoma is a cancer that occurs in the bladder, urethra, and renal pelvis and is associated with mutations in the FGFR (fibroblast growth factor receptor) gene. Erdafitinib is a targeted therapy drug that blocks the growth and division of cancer cells by inhibiting the FGFR signaling pathway, thereby inhibiting the development of tumors. It is mainly used for patients with metastatic or locally advanced urothelial cancer with FGFR gene mutations who are refractory to traditional treatments. Patients taking erdafitinib need to be treated under the supervision of a professional physician and undergo regular evaluation. Although erdafitinib may provide significant benefit in some patients, treatment effects vary among individuals. Therefore, treatment plans should be individualized based on the patient's specific circumstances.